

# NANOPARTICLES IN BIOTECHNOLOGY, DRUG DEVELOPMENT AND DRUG DELIVERY



**BIO113B**  
**August 2014**

Jackson Highsmith  
***Project Analyst***

ISBN: 1-56965-904-4

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, 2012-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	11
NANOPARTICLE OVERVIEW	11
<i>TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTIC IMAGING</i>	12
LIPOSOMES	13
QUANTUM DOTS	13
DENDRIMERS	13
MACROMOLECULE NANOPARTICLES	13
BRIEF HISTORY OF NANOPARTICLES	14
NANOPARTICLES IN BIOTECHNOLOGY	14
<i>TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY</i>	15
NANOPARTICLES IN DRUG DEVELOPMENT	15
<i>TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT</i>	16
NANOPARTICLES IN DRUG DELIVERY SYSTEMS	16
<i>TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS</i>	17
<i>TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS</i>	18
NANOPARTICLES IN DIAGNOSTIC IMAGING	19
<i>TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING</i>	20
MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY FIELD	20
<i>TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD</i>	21
<i>TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH 2019 (\$ MILLIONS)</i>	22
MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES	23
<i>TABLE 9 MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES, THROUGH 2014</i>	23
CHAPTER 4 GLOBAL MARKET FOR NANOPARTICLES IN LIFE SCIENCE	25
<i>TABLE 10 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 (\$ MILLIONS)</i>	25
GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY	25

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 11 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES, THROUGH 2019 (\$ MILLIONS)</i>	26
GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT	26
<i>TABLE 12 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION, THROUGH 2019 (\$ MILLIONS)</i>	27
GLOBAL MARKET FOR NANOPARTICLES IN DRUG DELIVERY SYSTEMS	27
<i>TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS, THROUGH 2019 (\$ MILLIONS)</i>	28
GLOBAL MARKET FOR NANOPARTICLES IN DIAGNOSTIC IMAGING	28
<i>TABLE 14 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS, THROUGH 2019 (\$ MILLIONS)</i>	29
GLOBAL DISTRIBUTION OF NANOBIO TECHNOLOGY AND NANOMEDICINE COMPANIES	29
<i>TABLE 15 GLOBAL DISTRIBUTION OF NANOBIO TECHNOLOGY AND NANOMEDICINE COMPANIES</i>	29
CHAPTER 5 NANOPARTICLES STRUCTURE	33
ADOPTION OF NANOPARTICLES IN APPLIED MARKETS	33
<i>TABLE 16 NANOPARTICLE STRUCTURE AND PROPERTIES</i>	33
LIQUID CRYSTALS	34
LIQUID CARRIERS	34
LIPOSOMES	34
DENDRIMERS	35
CHITOSAN AND ALGINATE	35
NANOCRYSTALS	35
QUANTUM DOTS	36
APPLICATION OF NANOPARTICLES TO DRUGS DELIVERED	37
<i>TABLE 17 NANOPARTICLE SYSTEMS APPROVED FOR DRUG DELIVERY</i>	37
CHAPTER 6 NANOPARTICLE PRODUCTION	40
METHOD OF NANOPARTICLE FORMATION	40
SELF-ASSEMBLY PRODUCTION	41
METHODS OF STABILIZATION	42
METHODS OF DRUG INTRODUCTION	42
POLYMERIC NANOPARTICLES	42
MICELLES	43
LIPOSOMES	43
<i>TABLE 18 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY</i>	43
GOLD AND SILICON NANOPARTICLES	44
DENDRIMERS	44
METHODS OF LOADING BIOLOGICAL MOLECULES INTO NANOPARTICLES	45
NANOCRYSTAL DRUGS	45
PROBLEMS WITH LARGE-SCALE NANOPARTICLE PRODUCTION	46
CHAPTER 7 NANOPARTICLES IN BIOTECHNOLOGY	49
<i>TABLE 19 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS</i>	49
RESEARCH AND DEVELOPMENT	50
STEM CELL RESEARCH	50

<b>TOPIC</b>	<b>PAGE NO.</b>
CELLULAR REPAIR	51
IN VITRO IMAGING	52
PARAMAGNETIC AND SUPERPARAMAGNETIC NANOPARTICLES	53
BIOSENSORS AND QUANTUM DOTS	53
QUANTUM DOTS	53
BIOSENSORS	54
<i>TABLE 20 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT</i>	54
NANOPARTICLE RESEARCH COLLABORATIVE PROGRAMS	56
<i>TABLE 21 ETPN STRATEGIC RESEARCH AND INNOVATION AGENDA</i>	56
CHAPTER 8 NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION	59
<i>TABLE 22 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS</i>	59
BIOSEPARATIONS	59
<i>TABLE 23 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN NANOPARTICLE DELIVERY SYSTEMS</i>	60
RAPID DRUG ANALYSIS	62
REMOVAL OF IMPURITIES AND TOXINS	62
USING NANOPARTICLES TO INCORPORATE INSOLUBLE DRUGS	63
<i>TABLE 24 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS</i>	64
GOLD AND SILVER NANOPARTICLES IN BIOMEDICINE	64
DNA NANOPARTICLE DEVELOPMENT OF DNA-SPECIFIC DRUGS	65
CHAPTER 9 NANOPARTICLES IN DRUG DELIVERY SYSTEMS	68
NANOPARTICLES IN DRUG DELIVERY APPLICATIONS	68
<i>TABLE 25 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS</i>	68
DESIGNING A NANOPARTICLE DRUG DELIVERY SYSTEM	69
NANOPARTICLE DRUG STABILITY	69
SIZE HOMOGENEITY OF NANOPARTICLE PREPARATIONS	70
DRUG LOADING OF NANOPARTICLES	71
DRUG RELEASE FROM NANOPARTICLE	71
EXTERNAL TRIGGERS FOR RELEASING DRUG FROM NANOPARTICLES	72
BINDING/INCORPORATION OF BIOMOLECULES TO NANOPARTICLES	72
NANOPARTICLE TOXICITY	74
LARGE-SCALE MANUFACTURING	75
METHODS OF ADMINISTRATION OF NANOPARTICLE DRUGS	77
<i>TABLE 26 STANDARD ROUTES OF DRUG ADMINISTRATION</i>	77
ORAL ADMINISTRATION	77
INJECTION ADMINISTRATION	78
TRANSDERMAL PATCH	78
<i>TABLE 27 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS</i>	78
IMPLANTATION ADMINISTRATION	79
INHALATION ADMINISTRATION	80
<i>NANOPARTICLES SUITABLE FOR DRUG DELIVERY SYSTEMS</i>	80
<i>TABLE 28 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS</i>	81
LIPID-BASED NANOPARTICLES	81
MICELLE NANOPARTICLES	82
DENDRIMER NANOPARTICLES	83
POLYMERIC NANOPARTICLES	83

<b>TOPIC</b>	<b>PAGE NO.</b>
METAL-BASED NANOPARTICLES	84
BIOLOGICAL MACROMOLECULE NANOPARTICLES	85
NANOCRYSTALS	86
<i>TABLE 29 NANOCRYSTAL DRUGS APPROVED BY THE FDA</i>	88
NANOPARTICLE DRUG DELIVERY SYSTEMS NOW AVAILABLE	89
ANTIBIOTIC NANOPARTICLES	89
ANTI-TUMOR AND SMALL MOLECULE DELIVERY BY NANOPARTICLE	90
RELEASE OF ANTI-CANCER DRUGS FROM NANOPARTICLES	95
BIOMACROMOLECULES DELIVERED BY NANOPARTICLES	97
NANOPARTICLE COATINGS FOR DRUG DELIVERY SYSTEMS	100
REMOVAL OF NANOPARTICLES FROM THE BODY	101
RENAL CLEARANCE	101
<i>TABLE 30 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY</i>	102
CHAPTER 10 IN VITRO AND IN VIVO DIAGNOSTIC IMAGING	104
IN VITRO IMAGING	104
NANOPARTICLES IN DIAGNOSTIC IMAGING	104
<i>TABLE 31 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING</i>	105
CHAPTER 11 BIOMEDICAL NANOPARTICLE PRODUCTS	109
FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS AND PRODUCTS	109
<i>TABLE 32 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS</i>	109
<i>TABLE 33 FDA-APPROVED DRUGS FOR CANCER TREATMENT</i>	111
<i>TABLE 34 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES</i>	113
<i>TABLE 35 FDA-APPROVED NANOPARTICLE DRUGS FOR INFECTIOUS DISEASES</i>	113
MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY SYSTEMS	114
<i>TABLE 36 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION MARKET</i>	114
COMPANY PIPELINES FOR NANOPARTICLE DRUG DELIVERY	115
<i>TABLE 37 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS</i>	115
<i>TABLE 38 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS</i>	118
<i>TABLE 39 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS</i>	119
<i>TABLE 40 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS</i>	120
<i>TABLE 41 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS</i>	123
<i>TABLE 42 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS</i>	126
<i>TABLE 43 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS</i>	128
DRIVERS OF NANOPARTICLE PRODUCTS AND MARKETING	129
LIMITERS OF NANOPARTICLE PRODUCT DEVELOPMENT AND MARKETING	129
CHAPTER 12 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DELIVERY SYSTEMS	132
THE GLOBAL MARKET	132
<i>TABLE 44 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 (\$ MILLIONS)</i>	132
<i>TABLE 45 REGIONAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 (\$ MILLIONS)</i>	133
<i>TABLE 46 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH 2019 (\$ MILLIONS)</i>	134

TOPIC	PAGE NO.
CHAPTER 13 CLINICAL TRIALS OF NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS	136
TABLE 47 DISTRIBUTION OF NANOPARTICLE DRUG CLINICAL TRIALS WITHIN DISEASE CATEGORIES	136
TABLE 48 CLINICAL TRIALS FOR NANOPARTICLE DRUGS FOR CANCER	137
TABLE 49 CLINICAL TRIALS FOR NANOPARTICLE DRUGS/PROCEDURES (NON-CANCER)	148
TABLE 50 CLINICAL TRIALS WITH NANOPARTICLE DRUGS (MISCELLANEOUS)	151
TABLE 51 RESPIRATORY SYNCYTIAL VIRUS NANOPARTICLE VACCINE CLINICAL TRIALS	152
TABLE 52 CLINICAL TRIALS FOR NANOPARTICLES FOR DIAGNOSTIC IMAGING	152
NANOPARTICLE DRUGS IN PRECLINICAL TESTING STAGE	153
TABLE 53 NANOPARTICLE DRUGS/CARRIERS IN PRECLINICAL EVALUATION	153
CHAPTER 14 PATENTS, LICENSING, MERGERS AND ACQUISITIONS	160
TABLE 54 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND ACQUISITION ACTIVITIES	160
NANOPARTICLE PATENTS	162
TABLE 55 GLOBAL PERCENTAGE OF PATENTS ISSUED BY GEOGRAPHY, THROUGH 2014	163
U.S. PATENTS FOR NANOPARTICLES DRUG DEVELOPMENT AND DELIVERY	163
TABLE 56 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT AND DELIVERY	163
TABLE 57 U.S. PATENTS FOR NANOCRYSTALLINE DRUGS	167
QUANTUM DOT PATENTS	168
TABLE 58 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL APPLICATIONS	169
CHAPTER 15 COMPANY PROFILES	171
ABRAXIS BIOSCIENCES, INC	171
PRODUCTS	171
STRATEGY	172
ACCESS PHARMA INC.	172
PRODUCTS	172
STRATEGY	173
ADVANCELL	173
STRATEGY	173
ALKERMES, PLC	173
PRODUCTS	174
STRATEGY	174
ALNYLAM PHARMACEUTICALS INC.	174
PRODUCTS	175
STRATEGY	175
AMAG PHARMACEUTICALS INC.	175
PRODUCTS	176
STRATEGY	176
ASTRAZENECA PHARMACEUTICALS, PLC	176
PRODUCTS	177
STRATEGY	177

<b>TOPIC</b>	<b>PAGE NO.</b>
BIND BOSCIENCES INC.	177
STRATEGY	178
CALGENE CORP.	178
STRATEGY	179
CAMURUS AB	179
STRATEGY	179
CAPSULATION AG	180
STRATEGY	180
CERAMISPHERE PTY LTD	180
STRATEGY	181
CERULEAN PHARMA INC.	181
STRATEGY	182
CYTIMMUNE SCIENCES	182
PRODUCTS	183
STRATEGY	183
DEBIOTECH, S.A.	183
PRODUCTS	184
STRATEGY	184
ELAN PHARMACEUTICALS INC.	185
PRODUCTS	186
STRATEGY	186
ENSEMBLE THERAPEUTICS	186
STRATEGY	187
FLAMEL TEHNOLOGIES, INC	187
PRODUCTS	188
STRATEGY	188
GE GLOBAL RESEARCH	188
STRATEGY	189
MAGFORCE NANOTECHNOLOGIES AG	189
PRODUCTS	190
STRATEGY	190
MERSANA THERAPEUTICS INC.	190
PRODUCTS	191
STRATEGY	192
MIV THERAPEUTICS INC	192
STRATEGY	193
NANOCARRIER CO., LTD.	193
PRODUCTS	194
STRATEGY	194
NANOFIBER SOLUTIONS	194
PRODUCTS	195
NANO INTERFACE TECHNOLOGY, INC	195
PRODUCTS	195
STRATEGY	196
NANO MED TECH	196
PRODUCTS	196
NANOPROBES, INC	197

<b>TOPIC</b>	<b>PAGE NO.</b>
STRATEGY	197
NANOSPHERE INC.	198
PRODUCTS	198
STRATEGY	199
NANOTHERAPEUTICS	199
STRATEGY	200
NOVARTIS INTERNATIONAL AG	200
PRODUCTS	201
STRATEGY	201
PHARMASOL CORP.	201
PRODUCTS	202
STRATEGY	202
SKYEPHARMA, PLC	202
PRODUCTS	203
STRATEGY	204
STARPHARMA HOLDINGS, LTD	204
PRODUCTS	204
STRATEGY	205
T2 BIOSYSTEMS INC.	205
PRODUCTS	205
PRODUCTS	206
STRATEGY	206
TALON THERAPEUTICS INC.	206
PRODUCTS	207
STRATEGY	207



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTIC IMAGING	12
TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY	15
TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT	16
TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS	17
TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS	18
TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING	20
TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD	21
TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH 2019 (\$ MILLIONS)	22
TABLE 9 MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES, THROUGH 2014	23
TABLE 10 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 (\$ MILLIONS)	25
TABLE 11 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES, THROUGH 2019 (\$ MILLIONS)	26
TABLE 12 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION, THROUGH 2019 (\$ MILLIONS)	27
TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS, THROUGH 2019 (\$ MILLIONS)	28
TABLE 14 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS, THROUGH 2019 (\$ MILLIONS)	29
TABLE 15 GLOBAL DISTRIBUTION OF NANOBIOENGINEERING AND NANOMEDICINE COMPANIES	29
TABLE 16 NANOPARTICLE STRUCTURE AND PROPERTIES	33
TABLE 17 NANOPARTICLE SYSTEMS APPROVED FOR DRUG DELIVERY	37
TABLE 18 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY	43
TABLE 19 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS	49
TABLE 20 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT	54
TABLE 21 ETPN STRATEGIC RESEARCH AND INNOVATION AGENDA	56
TABLE 22 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS	59
TABLE 23 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN NANOPARTICLE DELIVERY SYSTEMS	60
TABLE 24 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS	64
TABLE 25 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS	68
TABLE 26 STANDARD ROUTES OF DRUG ADMINISTRATION	77
TABLE 27 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS	78
TABLE 28 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS	81
TABLE 29 NANOCRYSTAL DRUGS APPROVED BY THE FDA	88
TABLE 30 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY	102
TABLE 31 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING	105
TABLE 32 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS	109
TABLE 33 FDA-APPROVED DRUGS FOR CANCER TREATMENT	111
TABLE 34 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES	113
TABLE 35 FDA-APPROVED NANOPARTICLE DRUGS FOR INFECTIOUS DISEASES	113
TABLE 36 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION MARKET	114

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 37 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS	115
TABLE 38 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS	118
TABLE 39 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS	119
TABLE 40 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS	120
TABLE 41 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS	123
TABLE 42 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS	126
TABLE 43 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS	128
TABLE 44 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 (\$ MILLIONS)	132
TABLE 45 REGIONAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 (\$ MILLIONS)	133
TABLE 46 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH 2019 (\$ MILLIONS)	134
TABLE 47 DISTRIBUTION OF NANOPARTICLE DRUG CLINICAL TRIALS WITHIN DISEASE CATEGORIES	136
TABLE 48 CLINICAL TRIALS FOR NANOPARTICLE DRUGS FOR CANCER	137
TABLE 49 CLINICAL TRIALS FOR NANOPARTICLE DRUGS/PROCEDURES (NON-CANCER)	148
TABLE 50 CLINICAL TRIALS WITH NANOPARTICLE DRUGS (MISCELLANEOUS)	151
TABLE 51 RESPIRATORY SYNCYTIAL VIRUS NANOPARTICLE VACCINE CLINICAL TRIALS	152
TABLE 52 CLINICAL TRIALS FOR NANOPARTICLES FOR DIAGNOSTIC IMAGING	152
TABLE 53 NANOPARTICLE DRUGS/CARRIERS IN PRECLINICAL EVALUATION	153
TABLE 54 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND ACQUISITION ACTIVITIES	160
TABLE 55 GLOBAL PERCENTAGE OF PATENTS ISSUED BY GEOGRAPHY, THROUGH 2014	163
TABLE 56 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT AND DELIVERY	163
TABLE 57 U.S. PATENTS FOR NANOCRYSTALLINE DRUGS	167
TABLE 58 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL APPLICATIONS	169

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, 2012-2019 (\$ MILLIONS)	8